MISSISSAUGA, ON, May 25, 2011 /CNW/ - Nuvo Research Inc. (TSX: NRI), a
specialty pharmaceutical company dedicated to building a portfolio of
products primarily for the treatment of pain, today announced that Dan
Chicoine, the Company's Chairman and Co-Chief Executive Officer, will
present at BioFinance 2011 on Wednesday, June 1, at 11:00 a.m. Eastern
Time. The conference will be held at the St. Andrew's Club & Conference
Centre in Toronto, Ontario.
Mr. Chicoine will provide a corporate update, including information
about the Company's portfolio of topical pain products and the recently
closed ZARS acquisition.
In addition, Mr. Chicoine will participate in a BioFinance panel
presentation titled, 'Strategic Alliances - The Pharma Perspective',
the same day at 9:00 a.m. Eastern Time.
Neither event is being webcast.
BioFinance is a prominent Canadian investor conference for the life
sciences industry. The two-day event brings together key industry
players interested in investment opportunities and issues affecting
companies in the life sciences sector. Presenting companies span a
range of industries including biologics, medical devices, drug
delivery, vaccines, and diagnostics.
About Nuvo Research Inc.
Nuvo Research is a publicly traded, Canadian pharmaceutical company,
headquartered in Mississauga, Ontario. The Company is building a
portfolio of products for the treatment of pain through internal
research and development and by in-licensing and acquisition. The
Company's Pain Group, located in West Chester, Pennsylvania, is focused
on the development and commercialization of topically delivered pain
products. The Company's product portfolio includes Pennsaid, Pliaglis,
and Synera. Pennsaid, a topical non-steroidal anti-inflammatory drug
(NSAID), is used to treat the signs and symptoms of osteoarthritis of
the knee. Pennsaid is sold in the United States by Mallinckrodt Inc.,
a Covidien company (NYSE: COV), in Canada by Paladin Labs Inc.
(TSX:PLB) and in several European countries. Pliaglis is a topical
local anesthetic cream, which is U.S. Food and Drug Administration
(FDA) approved to provide topical local analgesia for superficial
dermatological procedures. ZARS has licensed worldwide marketing
rights to Pliaglis to GaldermaPharma S.A., a global specialty
pharmaceutical company focused on dermatology. Synera is a topical
patch that combines lidocaine, tetracaine and heat, approved in the
United States to provide local dermal analgesia for superficial venous
access and superficial and in Europe, for surface anaesthesia of normal
intact skin. ZARS currently markets Synera in the U.S. and its
licensing partner, EuroCept International B.V., has initiated a
pan-European launch of Synera (under the name Rapydan) in several
European countries. Through its subsidiary, Nuvo Research AG, based in
Leipzig, Germany, the Company is also developing the compound WF10, for
the treatment of immune related diseases. For more information, please
SOURCE Nuvo Research Inc.
For further information:
about Nuvo, please contact:
Westwicke Partners LLC
Tel: (443) 213-0506